Security key
59102M104
Metagenomi Therapeutics, Inc. - Common stock, par value $0.0001 per share (MGX)
CUSIP: 59102M104
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common stock, par value $0.0001 per share
- Total 13F shares
- 11,662,818
- Total 13F value
- $25,306,458
- Share change
- -548,323
- SEC-reported price per share
- $2.17
- Number of holders
- 65
- Value change
- -$3,651,260
- Number of buys
- 40
- Number of sells
- 20
- Shares outstanding
- 37,837,562
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
65
Top holders
10
MGX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Metagenomi Therapeutics, Inc. SEC filings
Metagenomi Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59102M104
Recent filing periods:
Ownership snapshot
Top reported holders of MGX - Metagenomi Therapeutics, Inc. - Common stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
Novo Holdings A/S
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
3/4/5
Lead comparable stake: 4.8%
Showing 1-6 of 15 holder rows.
Quick read
Novo Holdings A/S leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Novo Holdings A/S's linked filing trail.
Comparable ownership
Top 5
Novo Holdings A/S
4.8%
RA CAPITAL MANAGEMENT, L.P.
3.9%
FARALLON CAPITAL MANAGEMENT, L.L.C.
3.5%
PFM Health Sciences, LP
3.3%
HHLR ADVISORS, LTD.
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
3/4/5
Company · 10%+ Owner
|
4.8%
|
$7,344,000
1,800,000 shares
|
— | 30 Jun 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
3.9%
|
$6,029,216
1,477,749 shares
|
— | 30 Jun 2024 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
3.5%
|
$5,480,260
1,343,201 shares
|
— | 30 Jun 2024 |
| PFM Health Sciences, LP |
13F
Company
|
3.3%
|
$5,169,368
1,267,002 shares
|
— | 30 Jun 2024 |
| HHLR ADVISORS, LTD. |
13F
Company
|
2.1%
|
$3,173,293
777,768 shares
|
— | 30 Jun 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.9%
|
$2,931,927
729,852 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
65
Shares
11,662,818
Rows available
65
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q1 2026 Across Filers
Q1 2026 holders
47
Q3 2024 holders
65
Holder diff
18
| Investor | Q1 2026 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend